Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

2013-09-19
Published : Sep-2013

Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on [email protected]  with (Treating Refractory Hematological Malignancies – Multiple Myeloma (MM)) / report name in subject line and your contact details.

The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed – NDMM and relapsed/ refractory – RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts.  The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

Detailed financial and competitive analysis of the companies leading in this field for this indication – Celgene, Amgen (post-acquisition of Onyx pharma), and MorphoSys are available within this full report.  Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late-stages of development available for in-licensing are highlighted in the report.  This report is built using primary and secondary research data and in-house proprietary database.

Complete report available @ http://www.reportsnreports.com/reports/268467-treating-refractory-hematological-malignancies-multiple-myeloma-mm-new-treatment-options-driving-in-licensing-and-ma.html.

Reasons to buy the report:

  • Useful for investors, Scientists, Business development managers of Pharma companies with focus in oncology to address the following-
  • What are the opportunities or new approaches to be deployed in the R&D of the company?
  • List of validated and new targets
  • In-licensing opportunities – Is the way to go forward and be in the race?
  • Commercial opportunity and companies’ valuation.

Buy a copy of this report by MP Advisors @ http://www.reportsnreports.com/purchase.aspx?name=268467Contact [email protected] for more details.

Key points discussed in the report:

  • Overview of the Disease and Unmet need
  • Drugs in the pipeline: NDMM & RRMM – Mechanism of Action (MoA) and Clinical Stage of development
  • Comparative Clinical data of Late-stage Pipeline in RRMM and NDDM
  • Ongoing Clinical trial Details of Key Drugs in Pipeline
  • Key milestones
  • MPA view on the Future of the drugs in the late-stage pipeline
  • Launch Timeline and Commercial Opportunity of Late-stage pipeline
  • M&A and Licensing deals in the last 5 years
  • In-licensing and/or M&A Opportunity
  • Detailed Company analysis includes Clinical data of drugs, Milestones, and Valuation – Amgen (AMGN), Celgene (CELG), and MorphoSys (MOR)

Contact [email protected]  / Call +1 888 391 5441 for further information on “Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A” report OR for any other market research and intelligence needs you may have for your business.

Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

Filed in: Biotechnology
More Reports
Title Price Buy Now

Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User – Global Forecast to 2027

“The stem cell assays market growth can be attributed to factors such as the rising demand for technologically advanced stem cell analysis instruments, increase in the prevalence of cancer & other diseases and rising number of biopharma and & biotechnology companies working on stem cell based therapies.” The stem cell assays market is projected to reach USD 4.5 Billion by 2027 from USD 1.9 Billion in 2022, at a CAGR of 17.7% during the forecast period. The growth of the market is projected to be driven by collaborations and agreements among market players for stem cell assay products & services, launch of new stem cell analysis systems such as flow cytometers and increase in R&D expenditure by biopharmaceutical and biotechnology companies. The viability/cytotoxici......
$

Nucleic Acid Isolation & Purification Market by Product (Kit, Reagent, Instrument), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, miRNA), Application (Drug Discovery, Diagnostics), End User (Pharma, Biotech) – Global Forecast to 2027

The nucleic acid isolation and purification market is expected to grow at a CAGR of 7.9% in the forecast period. The global nucleic acid isolation and purification market is projected to reach USD 9.2 billion by 2027 from USD 6.3 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth of this market can majorly be attributed to the increasing R&D activities as well as technological advancements and increasing automation. The emerging economies, improving regulatory and reimbursement scenario, and the growing adoption of molecular diagnostics and personalized medicines are expected to offer a wide range of growth opportunities for players in the market. However, the high cost of automated instruments is expected to hinder the growth of the market. As the world be......
$4950

Wound Care Biologics Market by Product (Biological Skin Substitutes, Topical Agents), Wound Type (Ulcers [Diabetic Foot, Venous, Pressure Ulcers], Surgical & Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers) – Global Forecast to 2027

“Rising number of road accidents and associated traumatic wounds and growing incidence of burn injuries are driving the overall growth of the wound care biologics market” The global wound care biologics market is valued at an estimated USD 1.8 billion in 2022 and is projected to reach USD 2.4 billion by 2027, at a CAGR of 5.4% during the forecast period. Market growth is driven by factors such as the growing incidence of burn injuries and the rising number of road accidents and associated traumatic wounds. However, the high cost of wound care biologic products and the risk associated with skin substitute failure are the major factors hampering the growth of this market. “The biological skin substitutes segment accounted for the highest growth rate in the wound care biologics ma......
$4950

Bioanalytical Testing Services Market by Type, Application (Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology), End User and Region (North America, Europe, APAC, Latin America, MEA) – Global Forecast to 2027

“The global bioanalytical testing services market is projected to grow at a CAGR of 15.6%” Bioanalytical testing involves analytical methods used for the detailed examination of biological and biotechnology products. Bioanalysis enables the quantitative measurement of drugs and their metabolites, biological molecules in unnatural locations or concentrations, DNA, and large molecules. The global bioanalytical testing services market is projected to reach USD 6.0 billion by 2027 from an estimated USD 2.9 billion in 2022, at a CAGR of 15.6% during the forecast period. “The Cell-based assays segment is expected to account for the largest share of the bioanalytical testing services market” The increasing prevalence of chronic diseases and the rising number of clinical trials ar......
$4950

Cell Analysis Market by Product & Service (Reagents & Consumables, Instruments), Technique (Flow Cytometry, High Content Screening), Process (Single-cell Analysis), End User (Pharmaceutical and Biotechnology Companies) – Global Forecast to 2027

“Single-cell analysis segment has gained significant traction in the recent years attributed to the widening applications of this technology in cancer research. This is further supplemented by the robust government initiatives targeted towards single-cell analysis research. The growth of the single-cell analysis segment is expected to drive the overall growth of the cell analysis market.” The global cell analysis market is projected to reach USD 28.6 Billion by 2027 from USD 17.7 Billion in 2022, at a CAGR of 10.1% during the forecast period. Key opportunities for the cell analysis market include, emerging economies, high risk of communicable diseases and pandemic outbreak, and increasing adoption of novel cellular assays in various cancer research applications. On the other hand, h......
$4950

3D Cell Culture Market by Type (Hydrogel, ECM, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation), Application (Cancer, Stem Cell, Toxicology, Tissue Engineering), End User (Pharma, Biotech, Research, Cosmetics), Region – Global Forecast to 2027

“Increasing focus on developing alternative methods to animal testing, growing focus on personalized medicine is driving the overall growth of the3D Cell culture market” The global 3D cell culture market is valued at an estimated USD 1.3 billion in 2022 and is projected to reach USD 2.6 billion by 2027, at a CAGR of 15.6% during the forecast period. The growth of this market is mainly driven by factors such as the increasing focus on developing alternative methods to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, a lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth of this market during the f......
$4950

Tangential Flow Filtration Market by Product (System, Membrane Filter), Material (PES, PVDF, PTFE), Technique (Ultrafiltration), Application (Final Product Processing, Raw Material Filtration), End User (Pharma, Biotech), Region – Global Forecast to 2027

“Growth in the tangential flow filtration market can be attributed to factors such as the growing advantages of tangential flow filtration over normal flow filtration, rising R&D spending in pharmaceutical & biotechnology industries and increasing adoption of single-use technologies.” The global tangential flow filtration market is projected to USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 13.2% during the forecast period. The rising advantages of tangential flow filtration over normal flow filtration, increasing adoption of single-use technologies, and growing R&D spending in pharma-biotech companies. On the contrary, the high capital investments for setting up new production facilities are expected to restrain the market growth. “In 2021 the s......
$4950

Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) – Global Forecast to 2029

“Increased focus on human microbiome therapy development to drive the growth of this market.” The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029. The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth. “By product segment, the drugs segment accounted for the largest share of huma......
$4950

Exosome Research Market by Product and services (Kits, Reagents, Instrument), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem cell, Dendritic cell-derived), End User – Global Forecast to 2026

“Increasing interest in exosome-based proceduresto Drive the Growth of Market” The exosome research market is valued at an estimated USD 144 million in 2021 and is projected to reach USD 661 million by 2026, at a CAGR of 35.6% during the forecast period, owing to increased funding for life sciences research, the high global prevalence of cancer, and the increasing interest in exosome-based procedures. “By product & service, the kits & reagents segment accounted for the largest share of the exosome research market” Based on product and service, the exosomes market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is further divided into antibodies, isolation, purification, quantitation kits & reagents, and other ki......
$4950

Metagenomic Sequencing Market by Product & Services (Reagent, Consumables, Instrument), Workflow (Sample Preparation, Sequencing), Technology (16S rRNA, Shotgun, Whole-genome), Application (Drug Discovery, Diagnostic) – Global Forecast to 2027

“Continuous technological innovations in NGS platforms is the key factors driving growth in the metagenomic sequencing market’’ The metagenomic sequencing market is expected to reach USD 4.3 billion by 2027 from USD 1.9 billion in 2022, at a CAGR of 18.4% during the forecast period. Growth in the metagenomic sequencing market is mainly driven by continuous technological innovations in NGS platforms, increasing initiatives and funding from government & private bodies for large-scale sequencing projects, declining costs of genome sequencing, and the significant applications of metagenomics in various fields. “By technology segment, the shotgun metagenomic sequencing segment accounted for the fastest-growing segment of the metagenomic sequencing market” Based on technol......
$4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy